Melodiol Global Health (Melodiol Global Health) 3-Year EBITDA Growth Rate : 46.00% (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Melodiol Global Health 3-Year EBITDA Growth Rate?

Melodiol Global Health's EBITDA per Share for the six months ended in Dec. 2023 was $-0.01.

During the past 3 years, the average EBITDA Per Share Growth Rate was 46.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 42.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Melodiol Global Health was 46.00% per year. The lowest was 14.50% per year. And the median was 38.70% per year.

Competitive Comparison of Melodiol Global Health's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Melodiol Global Health's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Melodiol Global Health's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Melodiol Global Health's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Melodiol Global Health's 3-Year EBITDA Growth Rate falls into.

Melodiol Global Health 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Melodiol Global Health (OTCPK:COPHF) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Melodiol Global Health 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Melodiol Global Health's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Melodiol Global Health (Melodiol Global Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Melodiol Global Health Ltd (OTCPK:COPHF) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

ME1:Australia

Address

145 Stirling Highway, Suite 5 CPC, Nedlands, WA, AUS, 6009

Website

https://www.cresopharma.com

Melodiol Global Health Ltd is engaged in developing, registering, and commercialization of pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health. Its brands include Mernova: A licensed producer of cannabis products in Canada for sale under the Ritual brand banner. Sierra Sage Herbs: US-based developer of plant-based, beauty, and personal care brands Green Goo, Southern Butter, and Good Goo. impACTIVE: CBD topical products for athletes. Halucenex: Clinical stage psychedelics research and development operation. Creso Pharma Switzerland: CBD-related research, development, and commercialization.

Melodiol Global Health (Melodiol Global Health) Headlines

From GuruFocus

Halucenex Life Sciences Inc. targets Australian market following landmark TGA decision

By PRNewswire PRNewswire • 02-08-2023

Sierra Sage Herbs Acquired By Creso Pharma

By PRNewswire PRNewswire • 02-07-2022